Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

In ST-segment elevation myocardial infarction, the echocardiographic parameters of microvascular obstruction are not associated with left ventricular remodeling at five years of follow-up.

Dregoesc MI, Iancu AC, Ober CD, Homorodean C, Bãlãnescu Ş, Bolboacã S.

Echocardiography. 2019 Jun;36(6):1103-1109. doi: 10.1111/echo.14371. Epub 2019 May 22.

PMID:
31116460
2.

Renal Failure Impact on the Outcomes of ST-Segment Elevation Myocardial Infarction Patients Due to a Left Main Coronary Culprit Lesion Treated Using a Primary Percutaneous Coronary Intervention.

Homorodean C, Iancu AC, Dregoesc IM, Spînu M, Ober MC, Tãtaru D, Leucuţa D, Olinic M, Olinic DM.

J Clin Med. 2019 Apr 25;8(4). pii: E565. doi: 10.3390/jcm8040565.

3.

Intravascular leiomyoma with intracardiac extension associated with hepatorenal polycystic disease.

Dregoesc IM, Bãlãnescu ŞM, Marc MC, Iancu AC.

Anatol J Cardiol. 2018 Oct;20(4):246-248. doi: 10.14744/AnatolJCardiol.2018.20726. No abstract available.

4.

Hypereosinophilic syndrome with cardiac involvement in a patient with multiple malignancies.

Dregoesc MI, Iancu AC, Lazar AA, Balanescu S.

Med Ultrason. 2018 Aug 30;20(3):399-400. doi: 10.11152/mu-1574.

5.

Endovascular treatment of an aortic aneurysm and patent ductus arteriosus.

Balanescu SM, Linte AL, Dregoesc IM, Marc MC, Iancu AC.

Anatol J Cardiol. 2018 Aug;20(2):130-131. doi: 10.14744/AnatolJCardiol.2018.67365. No abstract available.

6.

Pre-revascularization coronary wedge pressure as marker of adverse long-term left ventricular remodelling in patients with acute ST-segment elevation myocardial infarction.

Marc MC, Iancu AC, Ober CD, Homorodean C, Bãlãnescu Ş, Sitar AV, Bolboacã S, Dregoesc IM.

Sci Rep. 2018 Jan 30;8(1):1897. doi: 10.1038/s41598-018-20276-6.

8.

Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.

Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L; DAPT Study Investigators.

JAMA. 2016 Apr 26;315(16):1735-49. doi: 10.1001/jama.2016.3775. Erratum in: JAMA. 2016 Jul 19;316(3):350. JAMA. 2016 Jul 19;316(3):350.

9.

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators.

N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225.

10.

Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy.

Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; DAPT Study Investigators.

JACC Cardiovasc Interv. 2015 Oct;8(12):1552-62. doi: 10.1016/j.jcin.2015.05.026. Erratum in: JACC Cardiovasc Interv. 2015 Dec 21;8(14):1913.

11.

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.

Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, Gerstein HC, Johnston P, Køber LV, Lawson F, Lewis EF, Maggioni AP, McMurray JJ, Ping L, Probstfield JL, Solomon SD, Tardif JC, Wu Y, Pfeffer MA; ELIXA Investigators.

Am Heart J. 2015 May;169(5):631-638.e7. doi: 10.1016/j.ahj.2015.02.002. Epub 2015 Feb 12.

PMID:
25965710
12.

Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial.

Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators.

JAMA. 2015 Mar 17;313(11):1113-21. doi: 10.1001/jama.2015.1671. Erratum in: JAMA. 2015 Jun 2;313(21):2185. JAMA. 2016 Jul 5;316(1):105. JAMA. 2016 Jul 5;316(1):105.

13.

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.

Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators.

N Engl J Med. 2014 Dec 4;371(23):2155-66. doi: 10.1056/NEJMoa1409312. Epub 2014 Nov 16.

Supplemental Content

Loading ...
Support Center